HPS Pharmacies wish to advise that all brands are experiencing a supply interruption for salbutamol 5mg nebules as follows:
Ventolin® Nebules
Salbutamol 5mg/2.5mL
ARTG 12534
Salbutamol Cipla Inhalation Ampoules
Salbutamol 5mg/2.5mL
ARTG 115657
Normal supplies of Salbutamol Cipla 5mg inhalation ampoules are expected to resume by the end of March 2026 and supplies of Ventolin 5mg nebules are expected to return by the end of May 2026.
Ventolin® 2.5mg/2.5ml nebules are currently available.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that Smith & Nephew has discontinued Flamazine® cream as follows:
Flamazine® Cream Jar
Silver sulfadiazine 1.0% w/w, 500g
ARTG 159338
Flamazine® Cream Tube
Silver sulfadiazine 1.0% w/w, 50g
ARTG 159342
Internationally registered alternatives may be accessed via the Special Access Scheme (SAS), if required. One of these alternatives contains methylparaben as a preservative which should be considered when treating patients who are pregnant or breastfeeding. Please note, SAS alternatives may have long lead times.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Smith & Nephew on (02) 9857 3999 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that Aspen has discontinued Mivacron® ampoules as follows:
Mivacron® Ampoules
Mivacurium (as chloride) 20mg/10mL
ARTG 42947
There is no Australian-registered alternative product available. Internationally registered alternatives may be accessed via the Special Access Scheme (SAS), if required. Please note, SAS alternatives may have long lead times.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Aspen on 1300 659 646 or your pharmacist at HPS Pharmacies.
Download PDF
Further to DrugAlert vol 1027, HPS Pharmacies wish to advise that the supply disruption of Apresoline® (hydralazine) 20 mg Powder for Injection is ongoing. To ensure continuity of supply, HPS Pharmacies have organised and secured S19A and SAS stock.
Distribution of the S19A stock to the wholesaler has been completed and further stock is due to arrive in late January 2026. Additionally, to ensure sufficient cover until the next batches of S19A stock arrive, SAS product has also been released and is available to order from the wholesaler.
The alternative products are as follows:
- Hydrapres® 20 mg AMP 1 mL x 5 (S19A)
- Hydrapres® 20 mg AMP 1 mL x 5 (SAS).
The S19A and SAS alternatives are identical in active ingredient and strength to the Australian-registered product. However, there are differences in excipients and reconstitution requirements. Healthcare professionals should check the product carefully before use.
Normal supplies of Apresoline® ampoules are expected to resume by the end of March 2026.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that all brands of tranexamic acid 500mg tablets are continuing to experience a supply interruption as follows:
| Product |
ARTG |
Expected return date |
| APO-Tranexamic Acid |
272732 |
Late February 2026 |
| Cyklokapron® |
14463 |
End-March 2026 |
| Tranexamic Acid Lupin |
272729 |
Mid-January 2026 |
| Tranexamic Acid Waymade |
411630 |
Mid-January 2026 |
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that Atnahs Pharma Australia, in consultation with the Therapeutic Goods Administration (TGA), has issued a product recall for Famvir® tablets as follows:
Famvir® 500mg Tablets, 30 pack
Famciclovir 500mg
ARTG 67391
This product recall was initiated as 30 tablet packs of Famvir® 500mg have been found to contain two blisters of 10 tablets rather than the required three blisters of 10 tablets. This creates a theoretical risk of incomplete treatment for patients requiring the full 30 tablets.
The only batch affected by this notice is: WV100 (Expiry: Feb 2028)
Please inspect your stock and quarantine all affected products from the above batch. Affected products should be returned to the supplier for replacement stock.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Atnahs Pharma Australia at [email protected] or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that B Braun, in consultation with the Therapeutic Goods Administration (TGA), has issued a product recall for Gelofusine® as follows:
Gelofusine® Ecobag 500mL
Succinylated gelatin 20g/500mL
ARTG 78102
This product recall was initiated following reports of serious reactions associated with batch 250617641. Investigation has revealed a quality deviation in the manufacturing process which may have resulted in contamination with non-endotoxin pyrogens.
The only batch affected by this notice is: 250617641 (Expiry: 31 January 2027)
Please inspect your stock and quarantine all products from the affected batch. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact B Braun on 1800 251 705 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that multiple sponsors are experiencing a supply interruption for pramipexole 0.125mg and 0.25mg tablets as follows:
| Product |
ARTG |
Expected return date |
| APO-Pramipexole 0.125mg |
227666 |
Late January 2026 |
| Sifrol 0.125mg |
67238 |
Mid-December 2025 |
| Simipex 0.125mg |
172017 |
Late February 2026 |
| Simpral 0.125mg |
173139 |
Early January 2026 |
| APO-Pramipexole 0.25mg |
227667 |
Late January 2026 |
| Sifrol 0.25mg |
66484 |
Mid-December 2025 |
| Simipex 0.25mg |
172018 |
Late January 2026 |
| Simpral 0.25mg |
173138 |
Late-December 2025 |
An internationally registered alternative of pramipexole 0.125mg and 0.25mg tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Medsurge is anticipating a supply interruption for noradrenaline ampoules as follows:
Noradrenaline Medsurge 2 mg/2 mL Ampoules
Noradrenaline (norepinephrine) 2 mg/2 mL
ARTG 349471
This supply interruption is expected to occur between early December 2025 through to early January 2026.
Alternative option:
- Noradrenaline Medsurge 4 mg/4 mL ampoules may be used during this period.
- Both presentations are concentrated solutions for injection and must be diluted in a glucose-containing solution (e.g., 5% glucose solution in distilled water or 5% glucose in saline solution) before infusion.
- Please note the difference in dilution procedures for each product.
Dilution guidance (for average dosing):
- 2 mg/2 mL ampoule: Add 2 mL to 500 mL glucose solution.
- 4 mg/4 mL ampoule: Add 4 mL to 1 litre glucose solution, or draw 2 mL and dilute as above.
Please refer to the Product Information for more details.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Medsurge on 1300 788 261 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that all brands of tranexamic acid 500mg tablets are experiencing a supply interruption as follows:
| Product |
ARTG |
Expected return date |
| APO-Tranexamic Acid |
272732 |
Late January 2026 |
| Cyklokapron® |
14463 |
Late January 2026 |
| Tranexamic Acid Lupin |
272729 |
End-November 2025 |
| Tranexamic Acid Waymade |
411630 |
Early December 2025 |
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
